Pharyngeal Squamous Cell Carcinoma
Pharyngeal squamous cell carcinomas most frequently harbor alterations in TP53, PIK3CA, KMT2D, CDKN2A, and FBXW7 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PIK3CA Mutation, and KMT2D Mutation are the most common alterations in pharyngeal squamous cell carcinoma .
There are 2 clinical trials for pharyngeal squamous cell carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain pharyngeal squamous cell carcinoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).
Pembrolizumab, tak-981, and external beam radiation therapy are the most common interventions in pharyngeal squamous cell carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.